Dr. Carlos Telleria is a Professor in the Departments of Pathology and Oncology at McGill University, an Investigator in the Cancer Research Program of the Research Institute of the McGill University Health Center, and a member of the McGill Centre for Translational Research in Cancer. Over more than three decades of research in Argentina, the United States, and Canada, he has developed an interdisciplinary career connecting reproductive endocrinology, cancer biology, and translational therapeutics. His research has translated insights into hormone signaling and cellular stress into innovative therapeutic strategies for ovarian cancer. His laboratory pioneered the investigation of mifepristone as an anticancer agent, demonstrating in 2007 that it suppresses ovarian cancer growth independently of classical progesterone receptor signaling. Subsequent studies showed that antiprogestins and antiglucocorticoids inhibit tumor growth and metastatic behavior, enhance cisplatin sensitivity, and trigger lethal cellular stress. Building on this foundation, his laboratory established a drug-repurposing program using clinically approved agents, including nelfinavir and auranofin. His work has revealed mechanisms linking cellular stress, DNA damage, oxidative stress, and immunogenic cell death to therapeutic response. A central goal is to exploit these vulnerabilities to restore platinum sensitivity and develop new treatment strategies for platinum-resistant ovarian cancers.